BRIEF — EMA Concludes Review Of Ipidacrine — Containing Medicines
Sept 18 (Reuters) — EMA: Ema- Concludes Review Of Ipidacrine-containing Medicines, Recommended Restricting And Better Defining Approved Uses Ema: Ipidacrine No Longer Approved For Neuritis, Polyneuritis, Polyradiculoneuropathy, Myasthenic Syndrome Ema- Chmp Recommended Revising Approved Uses Of Ipidacrine To Align Them With Available Data And Current Standards Of Care Ema: Ipidacrine Use In Demyelinating Diseases Removed From Approved Indications (Reuters.Briefs@thomsonreuters.com;)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.